肿瘤患者输注血小板发生不良反应影响因素分析  

Factors for Adverse Reactions to Platelet Transfusions in Tumor Patients

作　　者：胡婷婷 王诗铭 王希文 海艳秋 孙婷 HU Ting-ting;WANG Shi-ming;WANG Xiwen(Cancer Hospital of China University,Liaoning Cancer Hospital&Institute,Shenyang 110042)

机构地区：[1]中国医科大学肿瘤医院,辽宁省肿瘤医院输血科,沈阳110042

出　　处：《临床输血与检验》2021年第4期464-468,共5页Journal of Clinical Transfusion and Laboratory Medicine

摘　　要：目的探讨分析肿瘤患者输注血小板发生不良反应的影响因素。方法回顾性调查分析2018年1月~12月在我院输注血小板的肿瘤患者有无输血不良反应,分为有不良反应组和无不良反应组,并对2组患者的年龄、性别、民族、血型、妊娠史、输血史、临床诊断、血小板输注量、血小板储存时间、血小板输注次数及血小板配合输注等因素进行单因素比较分析。Logistic回归分析影响输注血小板发生不良反应的危险因素。结果1086例输注血小板患者纳入研究,输血不良反应率6.72%(73/1086),包括非溶血性发热反应36例,过敏反应37例。比较2组输血史、血小板储存时间、血小板输注次数及血小板配合输注差异有统计学意义(P<0.05)。多因素回归分析血小板未配合输注(随机输注)(OR=2.113,95%CI:1.282~3.482,P=0.003)是影响输注血小板发生不良反应的危险因素。结论血小板配合输注可以减少肿瘤患者输血不良反应发生。Objective To discuss the factors associated with adverse reactions caused by platelet transfusions in patients with tumors.Methods A retrospective analysis of adverse reactions in tumor patients receiving platelet transfusions in a hospital between January and December 2018 was done.Patients were divided into adverse reaction group and nonadverse reaction group.Univariate analyses were conducted to assess the factors in the two groups,such as age,sex,ethnicity,blood type,history of pregnancy,history of blood transfusion,clinical diagnosis,platelet transfusion dosing,platelet storage time,platelet transfusion times and compatible platelet transfusions etc..Logistic regression analysis was conducted to analyze the independent risk factors affecting adverse reactions during platelet transfusion.Results A total of 1086 patients receiving platelet transfusions were included in the study.The rate of adverse reactions to transfusion was 6.72%(73/1086),including 36 patients with non-hemolytic fever and 37 patients with anaphylaxis.There were statistically significant differences between the two groups in transfusion history,platelet storage period,platelet transfusion times and HLA/HPAmatched platelet transfusions(P<0.05).Multivariate regression showed HLA/HPA-unmatched platelet transfusions(random transfusions)(OR=2.113,95%CI:1.282~3.482,P=0.003)was an independent risk factor for adverse reactions to platelet transfusion.Conclusion HLA/HPA-matched platelet transfusions can reduce the incidence of adverse transfusion reactions in tumor patients.

关 键 词：肿瘤患者 血小板输注 输血不良反应 影响因素 

分 类 号：R331.1[医药卫生—人体生理学]